Comparative Pharmacology
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus OZOBAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus OZOBAX.
CYCLOBENZAPRINE HYDROCHLORIDE vs OZOBAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
None Documented
None Documented
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant